Multifunctional DNA nanosphere as well as preparation method and application thereof

By designing multifunctional DNA nanospheres, combining MRI contrast agents and chemotherapy drugs, dual development and targeted treatment of gliomas have been achieved, solving the problem of unclear development and difficult chemotherapy drugs in the prior art to cross the blood-brain barrier, and improving the problem of unclear development and difficult chemotherapy drugs in the prior art. The accuracy and efficacy of the treatment.

CN118924907AActive Publication Date: 2024-11-12NANTONG YUNZHOU SOFTWARE TECH CO LTD

Patent Information

Application Number
CN202411013981.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

The existing MRI and fluorescence development technologies have problems such as unclear boundaries, non-targeting, and major side effects in glioma development, making it difficult to achieve accurate resection and effective chemotherapy, and chemotherapy drugs are difficult to cross the blood-brain barrier, resulting in poor efficacy.

Method used

Design a multifunctional DNA nanosphere to combine the MRI contrast agent Gd-DOTA-N3 and the fluorescent label Cy5-BHQ with the chemotherapeutic drug DOX through click chemical reactions, and build Y-shaped DNA, connect DNA and adaptive using the principle of DNA base complementary pairing. Ligand DNA realizes dual development of acid response and targeted chemotherapy, enhances MRI and fluorescence signals, and improves the targeting and efficacy of drugs.

Benefits of technology

Dual development and targeted treatment of gliomas are achieved, the accuracy and efficacy of the development signal are improved, the side effects are reduced, and surgical resection can be accurately guided and supplemented with postoperative chemotherapy, which significantly improves the patient's survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924907A_ABST
    Figure CN118924907A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to a multifunctional DNA nanosphere as well as a preparation method and application thereof. According to the present invention, the acid-responsive i-motif sequence, the EGFRvIII aptamer A32 sequence and the MRI contrast agent Gd-DOTA-N3 are combined to design the DNA nanosphere, such that the glioma MRI enhancement / fluorescence integrated dual development is achieved so as to obtain the glioma tumor development signal capable of meeting the clinical requirements; meanwhile, an acid-responsive i-motif sequence, an EGFRvIII aptamer A32 sequence, an MRI contrast agent Gd-DOTA-N3 and a chemotherapeutic drug doxorubicin (DOX) are combined, a Gd-DOTA-N3 and Cy5-BHQ fluorescent pair is modified on a specific base, and the novel multifunctional DNA nanosphere for glioma fluorescence / MRI imaging and treatment is prepared by utilizing a DNA base complementary pairing principle.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a multifunctional DNA nanosphere and a preparation method and application thereof. Background Art

[0002] Currently, magnetic resonance imaging (MRI) is the most effective means of examining the range of gliomas and determining the adjacent relationship of tumors. Different MRI sequence scans and gadolinium contrast agent enhanced scans can assist in glioma imaging and guide glioma surgical resection. However, MRI examinations, including enhanced scans, still have the following deficiencies in glioma imaging:

[0003] (1) MRI shows the preoperative tumor imaging range, which cannot represent the actual tumor boundary observed during surgery. The current MRI intraoperative navigation technology that uses MRI to guide the range of gliomas also has the problem of "brain tissue deformation and displacement". The navigation combined with intraoperative MRI (iMRI) technology has high operating costs and objectively prolongs the surgical anesthesia time, which greatly limits its widespread promotion in clinical practice.

[0004] (2) The current principle of MRI enhanced imaging is mainly based on the incompleteness of the walls of new blood vessels in gliomas. The contrast agent gadolinium can penetrate the tumor blood-brain barrier (tBBB) and accumulate in the expanded extracellular space of the tumor to achieve enhanced imaging of gliomas. It does not truly target glioma cells. Therefore, in cases such as low-grade gliomas with relatively intact tBBB, enhanced MRI imaging of the glioma range is not ideal. In addition, since the retention time of gadolinium in glioma tumor tissue is short, in order to ensure the enhancement effect, the actual dose of gadolinium used will remain in organs such as the kidney and liver, thereby increasing the risk of secondary damage to organs such as the kidney and liver.

[0005] (3) It is sometimes difficult to effectively differentiate between tumor pseudoprogression, local radiation necrosis and glioma recurrence that occur during glioma resection and adjuvant radiotherapy through MRI enhanced scanning.

[0006] Therefore, the above problems need to be solved in order to give full play to the advantages of MRI in glioma imaging. For tumor fluorescence imaging of glioma, although fluorescence-guided surgery (FGS) based on fluorescent agents such as 5-aminolevulinic acid (5-ALA) and fluorescein sodium (FLS-Na) has been used to define the scope of glioma during surgery, it still has many shortcomings:

[0007] (1) Clinical application found that the fluorescence range derived from 5-ALA during surgery does not match the range of enhanced MRI imaging: it usually exceeds the glioma tumor enhancement area shown by MRI; at the same time, the duration of 5-ALA fluorescence is still insufficient, and the imaging range and intensity are constantly attenuated. In addition, the interference of ambient light affects the accuracy of 5-ALA tumor fluorescence imaging during surgery to varying degrees;

[0008] (2) FLS-Na is used to visualize gliomas by destroying the tBBB and entering the tumor. Therefore, the fluorescence intensity of FLS-Na is not high in low-grade gliomas with relatively intact tBBB, and the visualization of tumors is not ideal. In addition, the duration of FLS-Na fluorescence is also limited. FLS-Na will experience intraoperative fluorescence diffusion and intensity attenuation, making the fluorescence coloring of structures such as the meninges in the surgical area more obvious, which makes it difficult to identify the scope of gliomas during long-term intraoperative visualization.

[0009] (3) More importantly, both 5-ALA and FLS-Na are non-specific glioma imaging agents and lack the ability to target and identify glioma tumor cells. They are bound to produce non-specific fluorescent staining other than glioma tumor cells to a certain extent, thus affecting the accurate judgment of the scope of glioma.

[0010] From the above, it can be seen that both glioma magnetic resonance imaging and intraoperative glioma fluorescence imaging are independent single tumor imaging modes. How to achieve integrated multimodal imaging of gliomas, realize the effective integration of intraoperative tumor fluorescence imaging and preoperative MRI imaging, especially MRI enhanced imaging, to verify and assist each other, overcome the respective shortcomings of current MRI and fluorescence imaging for glioma tumor imaging, and realize accurate resection of gliomas under multimodal imaging, is an urgent problem to be solved in current clinical glioma imaging-assisted surgery.

[0011] Chemotherapy is an important supplement for glioma treatment. However, even if surgical resection and chemotherapy drugs are combined to treat glioma within the maximum safety range, the survival time of most patients after surgery is still less than 2 years. The reasons include: (1) Conventional chemotherapy prevents the growth and division of cancer cells by interfering with DNA replication and cell mitosis, but most chemotherapy drugs are non-specific and will inevitably bring side effects. The serious adverse reactions caused by them are closely related to the high mortality rate of patients; (2) The existence of blood-brain barrier and blood-tumor barrier prevents the delivery of large molecule drugs and small molecule non-lipid soluble drugs. At the same time, the damage of blood vessels in the tumor site, the acidic microenvironment of tumor tissue and the highly invasive growth of glioma make the delivery of chemotherapy drugs for glioma a difficult problem; (3) In order to achieve effective drug concentration, high doses of chemotherapy drugs are often required, which can easily induce chemotherapy resistance in tumors and lead to poor efficacy and prognosis. Therefore, in recent years, a large number of nanoparticle-based drug delivery systems have emerged. Nanoparticle delivery systems can carry anticancer drugs across the blood-brain barrier to reach the lesion site. Nanotechnology provides more diverse options and strategies for drug development, and there is an urgent need to develop drug delivery systems that are specific to glioma cells, have mild side effects, and have good efficacy.

[0012] Gliomas are the most common primary intracranial tumors and most of them are malignant. Although there are currently a variety of treatment methods including surgical resection, radiotherapy and chemotherapy, it is regrettable that the comprehensive treatment efficacy of gliomas has stagnated in recent years, and gene therapy and immunotherapy have not been successful. The reasons include the following three points: (1) Gliomas are highly invasive, which makes it very difficult to completely remove gliomas surgically, which is also an important reason for the recurrence of gliomas after surgery; (2) Due to the existence of the blood-brain barrier and the blood-tumor barrier, chemotherapy drugs often have difficulty reaching the intracranial tumor area and have greater toxic side effects on normal tissues; (3) Chemoresistance is also one of the main reasons for patient recurrence and low survival rate. 40-50% of patients are resistant to temozolomide.

[0013] Therefore, the present invention focuses on the above issues and designs a multifunctional DNA nanosphere to achieve dual imaging of glioma MRI enhancement / fluorescence integration, in order to obtain glioma tumor imaging signals that can meet clinical needs. At the same time, by loading chemotherapy drugs, precise killing of glioma cells can be achieved, thereby obtaining significant tumor synergistic chemotherapy effects. Summary of the invention

[0014] The purpose of the present invention is to provide a multifunctional DNA nanosphere and its preparation method and application to solve the problems existing in the above-mentioned prior art. The preparation method provided by the present invention can obtain a multifunctional DNA nanosphere with dual development and capable of treating glioma.

[0015] To achieve the above object, the present invention provides the following solutions:

[0016] The present invention provides a method for preparing a DNA nanosphere for dual imaging of glioma, comprising the following steps:

[0017] Gd-DOTA-N3 and Y1-1 are covalently linked by a click chemistry reaction to obtain Gd-DOTA-N3-modified Y1-1; the nucleotide sequence of Y1-1 is shown in SEQ ID NO.7;

[0018] Y-DNA, L-DNA and A32 are mixed to obtain a mixed system; the Y-DNA includes Y1-1 modified by Gd-DOTA-N3 as shown in SEQ ID NO.7, Y2 as shown in SEQ ID NO.2 and Y3 as shown in SEQ ID NO.3; the L-DNA includes Linker 1 as shown in SEQ ID NO.4 and Linker 2 as shown in SEQ ID NO.5; the nucleotide sequence of A32 is shown in SEQ ID NO.6;

[0019] The mixed system is heated and then cooled to obtain a solution containing the DNA nanospheres.

[0020] Preferably, the molar ratio of Y1-1, Y2 and Y3 after Gd-DOTA-N3 modification in the Y-DNA is 1:1:1;

[0021] The molar ratio of Linker 1 to Linker 2 in the L-DNA is 1:1;

[0022] In the mixed system, the molar ratio of Y-DNA to L-DNA is 3:5, the molar ratio of A32 to L-DNA is 1:5, and the final concentration of Gd-DOTA-N3 is 9 μM.

[0023] Preferably, the heating treatment is carried out at a temperature of 95° C. and for a time of 5 minutes.

[0024] The present invention provides an application of DNA nanospheres prepared by the above-mentioned preparation method in the preparation of products for diagnosing gliomas.

[0025] The present invention provides a method for preparing a multifunctional DNA nanosphere for dual imaging and treatment of glioma, comprising the following steps:

[0026] Gd-DOTA-N3 and Y1-1 are covalently linked by a click chemistry reaction to obtain Gd-DOTA-N3-modified Y1-1; the nucleotide sequence of Y1-1 is shown in SEQ ID NO.7;

[0027] Y-DNA, L-DNA and A32 are mixed to obtain a mixed system; the Y-DNA includes Y1-1 modified by Gd-DOTA-N3 as shown in SEQ ID NO.7, Y2 as shown in SEQ ID NO.2 and Y3 as shown in SEQ ID NO.3; the L-DNA includes Linker 1 as shown in SEQ ID NO.4 and Linker 2 as shown in SEQ ID NO.5; the nucleotide sequence of A32 is shown in SEQ ID NO.6;

[0028] The mixed system is heated and then cooled to obtain a solution of multifunctional DNA nanospheres not loaded with DOX;

[0029] The multifunctional DNA nanosphere solution not loaded with DOX and doxorubicin are mixed and incubated to obtain the multifunctional DNA nanosphere.

[0030] Preferably, the molar ratio of Y1-1, Y2 and Y3 after Gd-DOTA-N3 modification in the Y-DNA is 1:1:1;

[0031] The molar ratio of Linker 1 to Linker 2 in the L-DNA is 1:1;

[0032] In the mixed system, the molar ratio of Y-DNA to L-DNA is 3:5, the molar ratio of A32 to L-DNA is 1:5, and the final concentration of Gd-DOTA-N3 is 9 μM.

[0033] Preferably, the heating treatment is carried out at a temperature of 95° C. and for a time of 5 minutes.

[0034] Preferably, the concentration of DNA nanospheres in the multifunctional DNA nanosphere solution not loaded with DOX is 3 μM; and the concentration of doxorubicin is 50 μM.

[0035] The present invention provides a multifunctional DNA nanosphere prepared by the above-mentioned preparation method.

[0036] The present invention provides the use of the multifunctional DNA nanosphere in preparing products for diagnosing and / or treating glioma.

[0037] The present invention discloses the following technical effects:

[0038] The present invention focuses on the above issues, combines the acid-responsive i-motif sequence, the EGFRvⅢ aptamer A32 sequence and the MRI contrast agent Gd-DOTA-N3, and designs DNA nanospheres to achieve MRI enhancement / fluorescence integrated dual imaging of gliomas, in order to obtain glioma tumor imaging signals that can meet clinical needs.

[0039] At the same time, the present invention combines the acid-responsive i-motif sequence, the EGFRvⅢ aptamer A32 sequence, the MRI contrast agent Gd-DOTA-N3 and the chemotherapy drug doxorubicin (DOX), modifies the Gd-DOTA-N3 and Cy5-BHQ fluorescence pairs on specific bases, and uses the principle of DNA base complementary pairing to prepare a new multifunctional DNA nanosphere for glioma fluorescence / MRI imaging and treatment. The present invention designs three modules based on the principle of DNA base complementary pairing, namely Y-shaped DNA (Y-DNA), connecting DNA (L-DNA) and aptamer DNA for preparing nanospheres. Y-DNA is composed of three single-stranded DNAs (Y1, Y2, Y3), each of which contains a sticky end. In order to achieve MRI enhanced imaging, a sequence containing an alkyne group is designed at the end of Y1, namely Y1-1, which can be covalently linked to Gd-DOTA-N3 through a click chemistry reaction, thereby introducing an MRI enhancer into the DNA nanosphere. The aptamer DNA is composed of an aptamer A32 that can specifically bind to EGFRvⅢ and a sticky end. Therefore, the aptamer DNA (A32) can inhibit the extension of the nanosphere and target EGFRvⅢ-positive glioma cells. L-DNA is a linear double-stranded chain assembled by Linker 1 and Linker 2, and contains two sticky ends complementary to the sticky ends of Y-DNA and A32. To achieve glioma fluorescence imaging, Cy5 is used to modify Linker 1. Considering that the continuous fluorescence signal of Cy5 will cause strong background interference, the BHQ-3 quenching group is modified on the Cy5 paired base to inhibit its fluorescence emission. When in an acidic environment, Linker 1 containing the i-motif sequence folds itself to form an i-motif structure, thereby separating from Linker 2, causing the DNA nanosphere to disintegrate, and restoring Cy5 fluorescence. It can be seen that the present invention achieves precise killing of glioma cells by loading chemotherapeutic drugs, thereby obtaining a significant tumor synergistic chemotherapy effect. The nanosphere has a fast pH response ability and can control the Cy5 fluorescence recovery and the release of DOX. Its fluorescence signal-to-noise ratio can reach 1:6 at pH = 5. The targeting ability of the aptamer A32 can increase the enrichment of the nanospheres in the glioma area, thereby improving the dual imaging effect of the DNA nanospheres. The sustained release effect of DNA nanospheres on DOX and the targeting ability of A32 can improve the tumor-killing efficacy of DOX. Through experimental verification, the DNA nanosphere has good dual imaging and targeted therapy of gliomas, and has the characteristics of strong specificity, high sensitivity, long duration, good stability, better chemotherapy effect, and lower side effects. It is expected to achieve precise guidance for surgical resection of gliomas and simultaneous postoperative chemotherapy.

[0040] It can be seen that the present invention prepares a multifunctional DNA nanosphere that can target glioma cells to achieve fluorescence / magnetic resonance dual imaging of glioma tumors, and improve the efficacy of doxorubicin (DOX) against gliomas, thereby achieving precise guidance of glioma surgical resection and simultaneous postoperative chemotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0042] Figure 1 The figure is a schematic diagram of the construction of multifunctional DNA nanospheres and their dual imaging and therapeutic functions for gliomas; wherein Cy5 is a Cy5 fluorescent group, BHQ3 is a BHQ-3 fluorescent group, GD is Gd-DOTA-N3, DOX is doxorubicin, and EGFRvⅢ is the EGFRvⅢ protein on the glioma cell membrane;

[0043] Figure 2 The characterization results of multifunctional DNA nanospheres; A is PAGE verification of DNA assembly, bands 1-7 are Y1, Y1+Y2, Y1+Y2+Y3, Linker 1, Linker2, Linker 1+Linker2 and multifunctional DNA nanoparticles respectively; B is the particle size analysis of DNA nanospheres with different molar ratios of Y-DNA and A32, a is the molar ratio of Y-DNA and A32 is 4:1, b is the molar ratio of Y-DNA and A32 is 3:1, c is the molar ratio of Y-DNA and A32 is 2:1; C is the TEM image of Y-DNA; D is the multifunctional DNA nanosphere with a molar ratio of Y-DNA to A32 of 3:1; E is the scanning electron microscopy observation result; F is the atomic force microscopy observation result; the scale bar of CF is 100nm;

[0044] Figure 3 TEM images of multifunctional DNA nanospheres with different molar ratios of Y-DNA and A32; A is the molar ratio of Y-DNA and A32 is 4:1; B is the molar ratio of Y-DNA and A32 is 2:1; the scale bars of A and B are 100 nm;

[0045] Figure 4The results of the study on the performance of DNA nanospheres loaded with DOX; wherein A is the fluorescence spectrum of the multifunctional DNA nanospheres as the pH changes; B is the comparison of the pH response ability of the DNA nanospheres prepared by L-DNA containing the i-motif sequence and L'-DNA composed of random sequences; C is the fluorescence spectrum of the multifunctional DNA nanospheres with different concentrations after incubation with 50μM DOX; D is the fluorescence spectrum of 3μM multifunctional DNA nanospheres after incubation with 50μM DOX at pH 7.25 and 5.5; L-DNA includes Linker 1 with a nucleotide sequence as shown in SEQ ID NO.4 and Linker 2 with a nucleotide sequence as shown in SEQ ID NO.5, and L'-DNA includes Linker 1-1 with a nucleotide sequence as shown in SEQ ID NO.8 and Linker 2-1 with a nucleotide sequence as shown in SEQ ID NO.9; i-motif is a multifunctional nanosphere containing L-DNA with an i-motif sequence, and control is a DNA nanosphere prepared by L'-DNA composed of a random sequence;

[0046] Figure 5 To study the reversibility of multifunctional DNA nanospheres between neutral pH (7.25) and acidic pH (5.00);

[0047] Figure 6 The T1-weighted imaging images of DNA nanospheres modified with different concentrations of Gd-DOTA-N3; wherein DNA-Gd is a DNA nanosphere modified with Gd-DOTA-N3, and DNA (control) is a DNA nanosphere without Gd-DOTA-N3 modification;

[0048] Figure 7Figure 2 shows the results of cytological behavior study of DNA nanospheres loaded with DOX; A shows the fluorescence intensity of Cy5 to quantify the absorption of multifunctional DNA nanospheres after U87 cells were incubated with 3 μM multifunctional DNA nanospheres for 1 h, 3 h and 5 h; B shows the quantification of the uptake of multifunctional DNA nanospheres in U87 or U87-E cells after incubation with 1 μM multifunctional DNA nanospheres for 1 h; C shows the uptake of DNA nanospheres in U87 and U87-E cells detected by flow cytometry after incubation with 1 μM multifunctional DNA nanospheres for 1 h; D shows the pH-responsive multifunctional DNA nanospheres to Lysosomes in living cells were imaged, and the yellow fluorescence was the co-localization of DNA nanospheres (red) and lysosomes (green) (bar = 30 μm); D was (bar = 30 μm), Hoechst was a nuclear stain, Cy5 was a Cy5 fluorescent group, Lysotrack was a lysosome tracer, and Merge was a fusion image; E was a representative fluorescence image of U87-E cells treated with DOX and A32-DNA-DOX (2.5 μg / mL) for 1 h, 2 h, 4 h, and 6 h, DNA-DOX was a multifunctional DNA nanosphere loaded with DOX, and Free DOX was free DOX;

[0049] Figure 8 The results of the cytotoxicity study of DNA nanospheres; A is the toxicity of DNA nanospheres to U87-E, U87, Hela, HA and 293T cells detected by CCK8, PBS is PBS, and DNAnanospheres are multifunctional DNA nanospheres; B is the IC value of free DOX and A32-DNA-DOX on the viability of U87-E cells 50 value;

[0050] Fig. 9 The results of the in vivo anti-tumor efficacy evaluation in mice; A is the T2-weighted MRI image of A32-DNA-DOX, DNA-DOX, free DOX, DNA nanospheres and PBS after treatment; B is the fluorescence imaging of the brain slices of glioma mice 2 hours after the tail vein injection of DNA nanospheres; C is the fluorescence image of glioma tissues and organs collected 2 hours after the tail vein injection of nanospheres;

[0051] Fig.10 The results of in vivo anti-tumor efficacy evaluation in mice; A is the T2-weighted MRI images after treatment with A32-DNA-DOX, DNA-DOX, free DOX, DNA nanospheres and PBS; B is the survival period of intracranial glioma-bearing mice in the A32-DNA-DOX, DNA-DOX, free DOX, DNA nanospheres and PBS groups; C is the weight change curve of glioma-bearing mice in the A32-DNA-DOX, DNA-DOX, free DOX, DNA nanospheres and PBS groups;

[0052] Fig.11 In vivo magnetic resonance imaging: T1 enhanced magnetic resonance imaging of glioma mice at different time points after intravenous injection of DNA nanospheres, where A is T1 weighted imaging; B is T2 weighted imaging; C is the T1 scan result of glioma mice 0.5h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres; D is the T1 scan result of glioma mice 1h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres; E is the T1 scan result of glioma mice 2h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres; F is the T1 scan result of glioma mice 4h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres; G is the T1 scan result of glioma mice 6h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres; H is the T1 scan result of glioma mice 12h after tail vein injection of Gd-DOTA-N3 modified DNA nanospheres. DETAILED DESCRIPTION

[0053] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0054] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0055] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0056] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0057] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0058] Example 1

[0059] A method for preparing DNA nanospheres for dual imaging and treatment of gliomas, the schematic diagram of which is shown in FIG. Figure 1 As shown, the steps are as follows:

[0060] Step 1: Gd-DOTA-N3 (manufacturer: Xi'an Qiyue Biotechnology Co., Ltd., product link: https: / / www.afzhan.com / chanpin / 12679228.html) was covalently linked to Y1-1 through a click chemistry reaction (the nucleotide sequence of Y1-1 is shown in Table 1, and the reaction system is shown in Table 2). The reaction product was then purified using a 3 kDa centrifugal filter to remove the reaction substrate and catalyst. The relative molecular mass of the product was detected by a mass spectrometer. The relative molecular mass of the product was 15180.4, which was recorded as Y1-1 modified by Gd-DOTA-N3.

[0061] Step 2: Add Y-DNA (Y1-1, Y2 and Y3 modified with Gd-DOTA-N3), L-DNA (Linker 1 and Linker 2) and A32 to 1× PBS buffer (10 mM Mg 2+ ), a mixed system is obtained, wherein the nucleotide sequences of Y1-1, Y2, Y3, Linker 1, Linker 2 and A32 after Gd-DOTA-N3 modification are shown in Table 1; the molar ratio of Y1-1, Y2 and Y3 after Gd-DOTA-N3 modification in Y-DNA is 1:1:1, and the molar ratio of Linker 1 and Linker 2 in L-DNA is 1:1; the molar ratio of Y-DNA to L-DNA is 3:5, and the molar ratio of A32 to L-DNA is 1:5; in the mixed system, the final concentration of L-DNA is 5μM, the final concentration of Gd-DOTA-N3 is 9μM, and the final concentration of DNA nanospheres is 3μM. In this step, the size of the DNA nanospheres can be controlled by adjusting the molar ratio of Y-DNA to A32, and the average size of the DNA nanospheres in this step is about 150nm.

[0062] Step 3: Heat the mixed system in step 2 to 95°C, and slowly cool to room temperature after 5 minutes (to perform DNA single-strand hybridization reaction) to obtain a DNA nanosphere mixed solution, in which the concentration of DNA nanospheres in the mixed solution is 3 μM, i.e., multifunctional DNA nanospheres without DOX loading. In this step, heating to 95°C denatures the DNA, and then anneals, which is conducive to DNA hybridization.

[0063] Step 4: Incubate 50 μM DOX with the DNA nanosphere mixture obtained in step 3 at room temperature for 1 hour, purify and concentrate the product with a 10 kDa centrifugal filter, resuspend in PBS buffer and store at 4°C to obtain multifunctional DNA nanospheres loaded with DOX. The concentration of DNA nanospheres in the DNA nanosphere mixture used in this step is 3 μM, and the concentration of DOX used is 50 μM, which can saturate the DNA nanospheres with DOX.

[0064] Table 1 Single-stranded DNA sequences used in this example

[0065]

[0066] Note: If modification with contrast agent is not required, the sequence of Y1 can be used.

[0067] Table 2 Click chemistry reaction system

[0068] Reagent Name (Concentration) dose 1× PBS 60μL sodium ascorbate (10mM) 120μL Cu(II) sulfate (10 mM) 6μL tris-hydroxypropyltriazolylamine(10mM) 36μL <![CDATA[Gd-DOTA-N3]]> 2mg (overdose) Y1-1(100μM) 30μL

[0069] Example 2 Characterization of multifunctional DNA nanospheres

[0070] The successful self-assembly of the multifunctional DNA nanospheres without DOX prepared in Example 1 was verified by polyacrylamide gel electrophoresis (PAGE). Figure 2 As shown in A, band 7 represents the successful assembly of DNA nanospheres. Compared with other components, it has the largest molecular weight and the slowest migration, indicating that DNA self-assembly successfully forms nanospheres.

[0071] Next, dynamic light scattering (DLS) and transmission electron microscopy (TEM) were used to study the effect of the addition ratio of Y-DNA and A32 on the size of DNA nanospheres. Y-DNA and A32 were mixed at different molar ratios of 4:1, 3:1 and 2:1, while the concentration of L-DNA was 5 μM. Multifunctional DNA nanospheres without DOX loading were prepared according to the preparation method of Example 1. The ratio of the sticky ends of Y-DNA and A32 to the sticky ends of L-DNA was 1:1, ensuring that ssDNA was fully reacted. DLS results ( Figure 2 Figure B) shows that different ratios of Y-DNA and A32 can lead to different nanosphere sizes; a higher ratio of A32 leads to a smaller diameter of the nanosphere. TEM shows that the DNA nanospheres have a 3D spherical shape, and the diameter is consistent with the DLS results ( Figure 2 CD and Figure 3 ). When the ratio of Y-DNA to A32 is 3:1, the average particle size of DNA nanospheres is about 134nm.

[0072] The size was further confirmed by scanning electron microscopy (SEM) and atomic force microscopy (AFM). Figure 2 The size of the nanoparticles is of great clinical significance, as sizes <200 nm can prolong blood circulation time; therefore, 134 nm multifunctional nanospheres were used in subsequent experiments.

[0073] Linker 1 tends to form an i-motif structure in an acidic environment, thereby dissociating from its complementary chain, thereby increasing the distance between the Cy5 and BHQ-3 fluorescence pairs, causing the Cy5 fluorescence signal to be restored, thereby generating a fluorescence signal. Therefore, the pH response ability of the multifunctional DNA nanospheres prepared in Example 1 without DOX loading was detected by fluorescence emission spectroscopy, and DNA nanospheres prepared with L'-DNA without an i-motif structure were used as a control. The multifunctional DNA nanospheres containing an i-motif structure and the DNA nanospheres without an i-motif structure were placed in buffer solutions of different pH values, and the fluorescence intensity was measured. The results showed that the fluorescence intensity of Cy5 gradually increased with decreasing pH, and the signal-to-noise ratio reached 1:6 ( Figure 4 In contrast, Linker 1-1 and Linker 2-1, which do not contain the i-motif structure, did not induce the dissociation of DNA nanospheres ( Figure 4 In addition, the fluorescence intensity of the multifunctional DNA nanospheres prepared in Example 1 without DOX loading showed good reproducibility between the pH neutral solution (pH = 7.25) and the acidic solution (pH = 5.0) ( Figure 5 ). This study showed that the multifunctional DNA nanospheres only produced fluorescence after entering the lysosomes of glioma cells.

[0074] DOX can be excited to emit green or red fluorescence. When DOX is embedded in the DNA double strand, this fluorescence can be quenched. Therefore, the ability of DNA nanospheres to carry DOX was evaluated by fluorescence spectroscopy analysis. Different concentrations of DOX-loaded multifunctional DNA nanosphere solutions were incubated with 50μM DOX for 1h and fluorescence analysis was performed. The spectrum showed that when the concentration of the multifunctional DNA nanospheres reached 2μM, the DOX loading was almost saturated ( Figure 4 C in Figure 1). Therefore, 3 μM DNA nanospheres were used to supersaturate with 50 μM DOX in subsequent experiments. Since Linker 1 can dissociate from its complementary strand in an acidic environment, part of the DOX embedded in the DNA double strand can be quickly released in an acidic environment ( Figure 4 D).

[0075] For enhanced MRI imaging, Gd-DOTA-N3 was covalently linked to alkyne-modified Y1 via click chemistry, thereby introducing the MRI enhancer into the multifunctional DNA nanospheres. T1-weighted scanning showed that the Gd-DOTA-N3-modified multifunctional DNA nanosphere solution had good T1-enhanced imaging effect, which was positively correlated with the concentration of Gd-DOTA-N3 in the solution ( Figure 6 ).

[0076] Example 3 Cellular uptake and targeting ability of multifunctional DNA nanospheres

[0077] In order to verify whether cells can actively take up multifunctional DNA nanospheres, DNA nanospheres were assembled using the Linker 2 sequence of unmodified BHQ-3, and the preparation method was the same as in Example 1, so that the uptake of DNA nanospheres can be quantified by measuring the fluorescence intensity of Cy5. U87 cells were incubated with multifunctional DNA nanospheres (3 μM) for 1 h, 3 h, and 5 h, and then photographed. The results showed that Cy5 fluorescence was clearly localized outside the cell nucleus, and its red fluorescence intensity increased with the extension of the culture time, indicating that cells can actively take up nanospheres, and the uptake amount is positively correlated with time ( Figure 7 A in the figure). U87-E cells (U87-EGFRv III cells, purchased from ATCC cell bank) highly express EGFRv III, and A32 can increase the uptake of DNA nanospheres by U87-E cells. After the multifunctional DNA nanospheres were incubated with U87 and U87-E cells for 1 hour, the statistical bar graph and flow cytometry graph showed that the uptake of multifunctional DNA nanospheres by U87-E cells was higher than that by U87 cells ( Figure 7 B and C in ).

[0078] Example 4 Co-localization analysis of multifunctional nanospheres and lysosomes

[0079] Lysosomes are acidic organelles in cells with an internal pH of approximately 5.0. When multifunctional DNA nanospheres not loaded with DOX are engulfed into cells, they dissociate and release Cy5 fluorescence. To verify this concept, multifunctional DNA nanospheres not loaded with DOX (3 μM) were incubated with U87-E cells for 1 h, 3 h, and 6 h, and lysosomes were labeled with a green fluorescent probe. Fluorescence images show that the red fluorescence of Cy5 and the green fluorescence of lysosomes co-localize (yellow part) ( Figure 7 D). A considerable portion of the red and green fluorescence was separated, which may be due to the escape of some DNA structures from the lysosome.

[0080] Example 5 Release and toxicity of multifunctional nanospheres in U87-E cells

[0081] In order to study the DOX release of the DOX-loaded multifunctional DNA nanospheres (A32-DNA-DOX) prepared in Example 1, U87-E cells were co-cultured with A32-DNA-DOX or free DOX for 1, 2, 4, and 6 h. Fluorescence images showed that after 1 h of incubation, free DOX could enter the interior of the cell nucleus, while most of A32-DNA-DOX remained in the cytoplasm. After further incubation, A32-DNA-DOX also gradually showed nuclear localization ( Figure 7 E).

[0082] CCK8 experiment was used to study the toxicity of DOX-loaded multifunctional DNA nanospheres to different cells (U87-E cells, U87 cells, Hela cells, HA cells and 293T cells), and PBS was used as a control. The results showed that the multifunctional DNA nanospheres with a concentration below 10 μM had no cytotoxicity to various cells, showing good biocompatibility ( Figure 8 In contrast, the results of the CCK8 assay showed that the cytotoxicity of both free DOX and A32-DNA-DOX was concentration-dependent, with A32-DNA-DOX exhibiting higher cytotoxicity than free DOX ( Figure 8 B in Figure 2). This may be attributed to the controlled release of DOX in the cytoplasm. In an acidic environment, the acid-responsive part of the DOX-loaded multifunctional DNA nanospheres rapidly releases the loaded DOX, which is equivalent to the first dose of clinical administration, while the remaining DOX can be gradually released from the double strands under acidic conditions to provide a maintenance dose, which makes the retention rate of DOX in cells higher, thereby increasing cytotoxicity.

[0083] Example 6 Targeted fluorescence imaging of multifunctional DNA nanospheres in mice

[0084] In order to confirm whether the multifunctional DNA nanospheres without DOX prepared in Example 1 can enter the tumor area through the blood circulation, 0.1 mL of the multifunctional nanosphere solution (3 μM) was injected into the glioma mice through the tail vein, and the in vivo imaging system was used for detection (Schematic diagram of the dual imaging and therapeutic functions of the multifunctional DNA nanospheres on glioma). The results showed that obvious fluorescence signals could be observed in the tumor area ( Fig. 9 In addition, the brain tissue of the mice was collected 2 hours after injection for frozen sections and Cy5 fluorescence was detected. Compared with normal brain tissue, significant fluorescence was observed in the tumor area, indicating that the DNA nanospheres can effectively accumulate in the tumor area ( Fig. 9 Similarly, the imaging capability of the DNA nanospheres was explored in mice with subcutaneous gliomas. In vitro organ imaging was performed 2 h after tail vein injection, and Cy5 fluorescence signals were observed in subcutaneous glioma tissues ( Fig. 9 In conclusion, the multifunctional DNA nanospheres have good glioma targeting imaging capabilities.

[0085] Example 7 Anti-glioma effect of DOX-loaded multifunctional DNA nanospheres in vivo

[0086] In order to study the anti-glioma efficacy of the multifunctional DNA nanospheres without DOX and loaded with DOX prepared in Example 1, MRI scans were performed on the mice in each experimental group (A32-DNA-DOX group: injected with the multifunctional DNA nanospheres loaded with DOX prepared in Example 1; DNA-DOX group: injected with DNA nanospheres without A32, the preparation method was the same as in Example 1, except that the aptamer A32 was not used; Free DOX injected with DOX; DNA nanospheres group: injected with multifunctional DNA nanospheres without DOX; PBS group: injected with PBS; the injection amount of DOX for each treatment was 4 mg / kg, once every two days, for a total of 14 days) 2, 3 and 4 weeks after U87-E cells were implanted into the mice's skull. The results showed that the glioma tumors in A32-DNA-DOX and DNA-DOX grew more slowly than those in the multifunctional DNA nanospheres, free DOX and PBS groups ( Fig.10 A).

[0087] In addition, the survival time and weight changes of 7 tumor-bearing mice in each group were recorded, and the results showed that the survival time of the A32-DNA-DOX or DNA-DOX group was significantly longer than that of the other groups ( Fig.10 B), indicating that the multifunctional DNA nanospheres loaded with DOX have better efficacy in inhibiting tumor growth. The weight loss rate of intracranial glioma-bearing mice in the A32-DNA-DOX group and the DNA-DOX group was slower than that in the other groups, which also indicates the effectiveness of the treatment ( Fig.10 C).

[0088] Example 8 Magnetic resonance enhancement capability of multifunctional DNA nanospheres in vivo

[0089] The method prepared in Example 1 was used to prepare Gd-DOTA-N3 modified multifunctional DNA nanospheres with a concentration of 30 μM. After 0.1 mL of multifunctional DNA nanospheres were injected into the tail vein at different times (0.5, 1, 2, 4, 6 and 12 h), T1 scans were performed on mice with gliomas. The results showed that uneven enhancement was observed in the glioma area, indicating that the multifunctional DNA nanospheres have a certain enhanced imaging capability ( Fig.11 ).

[0090] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for preparing DNA nanospheres for dual imaging of glioma, characterized in that: The following steps are involved: Gd-DOTA-N3 and Y1-1 are covalently linked by a click chemistry reaction to obtain Gd-DOTA-N3-modified Y1-1; the nucleotide sequence of Y1-1 is shown in SEQ ID NO.7; Y-DNA, L-DNA and A32 are mixed to obtain a mixed system; the Y-DNA includes Y1-1 modified by Gd-DOTA-N3 as shown in SEQ ID NO.7, Y2 as shown in SEQ ID NO.2 and Y3 as shown in SEQ ID NO.3; the L-DNA includes Linker 1 as shown in SEQ ID NO.4 and Linker 2 as shown in SEQ ID NO.5; the nucleotide sequence of A32 is shown in SEQ ID NO.6; The mixed system is heated and then cooled to obtain a solution containing the DNA nanospheres.

2. The preparation method according to claim 1, characterized in that: The molar ratio of Y1-1, Y2 and Y3 after Gd-DOTA-N3 modification in the Y-DNA is 1:1:1; The molar ratio of Linker 1 to Linker 2 in the L-DNA is 1:1; In the mixed system, the molar ratio of Y-DNA to L-DNA is 3:5, the molar ratio of A32 to L-DNA is 1:5, and the final concentration of Gd-DOTA-N3 is 9 μM.

3. The preparation method according to claim 1, characterized in that: The temperature of the heating treatment is 95° C. and the time is 5 minutes.

4. Use of DNA nanospheres prepared by the preparation method according to any one of claims 1 to 3 in the preparation of products for diagnosing gliomas.

5. A method for preparing multifunctional DNA nanospheres for dual imaging and treatment of glioma, characterized in that: The following steps are involved: Gd-DOTA-N3 and Y1-1 are covalently linked by a click chemistry reaction to obtain Gd-DOTA-N3-modified Y1-1; the nucleotide sequence of Y1-1 is shown in SEQ ID NO.7; Y-DNA, L-DNA and A32 are mixed to obtain a mixed system; the Y-DNA includes Y1-1 modified by Gd-DOTA-N3 as shown in SEQ ID NO.7, Y2 as shown in SEQ ID NO.2 and Y3 as shown in SEQ ID NO.3; the L-DNA includes Linker 1 as shown in SEQ ID NO.4 and Linker 2 as shown in SEQ ID NO.5; the nucleotide sequence of A32 is shown in SEQ ID NO.6; The mixed system is heated and then cooled to obtain a solution of multifunctional DNA nanospheres not loaded with DOX; The multifunctional DNA nanosphere solution not loaded with DOX and doxorubicin are mixed and incubated to obtain the multifunctional DNA nanosphere.

6. The preparation method according to claim 5, characterized in that: The molar ratio of Y1-1, Y2 and Y3 after Gd-DOTA-N3 modification in the Y-DNA is 1:1:1; The molar ratio of Linker 1 to Linker 2 in the L-DNA is 1:1; In the mixed system, the molar ratio of Y-DNA to L-DNA is 3:5, the molar ratio of A32 to L-DNA is 1:5, and the final concentration of Gd-DOTA-N3 is 9 μM.

7. The preparation method according to claim 5, characterized in that: The temperature of the heating treatment is 95° C. and the time is 5 minutes.

8. The preparation method according to claim 5, characterized in that: The concentration of the DNA nanospheres in the multifunctional DNA nanosphere solution not loaded with DOX is 3 μM; the concentration of the doxorubicin is 50 μM.

9. A multifunctional DNA nanosphere prepared by the preparation method according to any one of claims 5 to 8.

10. Use of the multifunctional DNA nanosphere according to claim 9 in preparing products for diagnosing and / or treating glioma.

Citation Information

Patent Citations

  • Methods and composition for determining ph

    CN108350466A

  • Three-branch-like nucleic acid nano silver fluorescent cluster as well as preparation method and application

    CN108359448A

  • Multi-branched nucleic acid nano-silver fluorescent cluster and preparation method and purpose thereof

    CN108485654A

  • Nuclear magnetism-optical dual-mode imaging biconical DNA nanoprobe, and preparation method and application thereof

    CN110257374A

  • Application of nucleic acid aptamer to preparation of drug for treating Alzheimer's disease (AD)

    CN110384712A

Cited By

  • Nucleic acid nano hybrid material as well as preparation method and application thereof

    CN120078899A

  • Multifunctional DNA nanosphere, preparation method therefor, and use thereof

    WO2026021204A1